CD276 and neoplasm: Enoblituzumab (MGA271), a humanized IgG1 monoclonal antagonistic B7-H3 antibody, has been studied in phase I clinical trial in patients with refractory B7-H3-expressing neoplasms such as melanoma and advanced solid tumors (NCT01391143).